Nyrada AGM Presentation -James Bonnar CEO

Summary
›Pioneering transient receptor potential canonical (TRPC) channel blocking therapies.
›First-in-class neuroprotection and cardioprotection therapy with novel mode of action.
›One drug asset targeting two significant therapeutic areas and three large markets.